Epithelioid Sarcoma Treatment Market 2032: EMA, PDMA, FDA Approval, Clinical Trials, Medication, Epidemiology, NICE Approvals, Prevalence, Therapies and Companies by DelveInsight

Epithelioid Sarcoma Treatment Market

(Albany, USA) DelveInsight’s “Epithelioid Sarcoma Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Epithelioid Sarcoma, historical and forecasted epidemiology as well as the Epithelioid Sarcoma market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Epithelioid Sarcoma market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Epithelioid Sarcoma market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Epithelioid Sarcoma treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Epithelioid Sarcoma market.

To Know in detail about the Epithelioid Sarcoma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Epithelioid Sarcoma Market Forecast

Some of the key facts of the Epithelioid Sarcoma Market Report:

• The Epithelioid Sarcoma market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• In April 2025, Epizyme announced results of a Phase 1b/3 Global, Randomized, Double-blind, Placebo-Controlled Trial of Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma
• In November 2024, Haihe Biopharma Co., Ltd announced results of a Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of HH2853 in Patients with Relapsed/Refractory Non-Hodgkin’s Lymphomas or Advanced Solid Tumors
• As per the estimation of DelveInsight, there were 68 cases of ES in 2021, in the US, which was 37% of overall cases of 7MM
• According to DelveInsight’s estimation, 68 occurrences of ES, or 37% of all cases of 7MM, were reported in the US in 2021
• Germany reported the most ES cases among the EU-5 in 2021 (24 cases), followed by Italy (21 instances) and France (20). Spain has the fewest cases (13 cases)
• Epithelioid sarcomas are uncommon, accounting for fewer than 1% of soft tissue sarcomas, and exhibit a preference for men (up to a 2:1 male to female ratio), according to Needs et al. (2022). The majority of reported tumours affect young boys between the ages of 10 and 45. With a median age of 27, the range of ages includes 4 to 90
• Key Epithelioid Sarcoma Companies: Epizyme, Eli Lilly and Company, Pfizer, Merck Sharp & Dohme, GlaxoSmithKline and Among Others
• Key Epithelioid Sarcoma Therapies: Tazemetostat in Combination With Doxorubicin, Doxorubicin HCl, Talimogene Laherparepvec (T-VEC), and others
• The Epithelioid Sarcoma market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Epithelioid Sarcoma pipeline products will significantly revolutionize the Epithelioid Sarcoma market dynamics.

Epithelioid Sarcoma Overview

Epithelioid sarcoma is a rare and aggressive type of soft tissue cancer that most commonly affects young adults. Epithelioid sarcoma typically begins as a slow-growing lump under the skin, often in the extremities such as the hands, forearms, or feet, but can also occur in the trunk and other deep soft tissues. Epithelioid sarcoma is characterized by its tendency to recur locally and its potential to spread to lymph nodes and distant organs, particularly the lungs.

Epithelioid sarcoma diagnosis involves a combination of imaging studies and a biopsy, followed by immunohistochemistry to distinguish it from other tumors. Epithelioid sarcoma is often misdiagnosed due to its resemblance to benign conditions. Epithelioid sarcoma treatment typically includes surgical resection with wide margins, but radiation therapy and chemotherapy may also be recommended based on the tumor’s stage and location.

Epithelioid sarcoma has limited treatment options, but recent advancements include targeted therapies and clinical trials exploring novel agents. Epithelioid sarcoma patients often require long-term monitoring due to high recurrence rates. Epithelioid sarcoma awareness and research funding are crucial for improving outcomes and developing new therapies. Epithelioid sarcoma prognosis varies based on early detection and comprehensive treatment strategies.

Get a Free sample for the Epithelioid Sarcoma Market Report: Epithelioid Sarcoma Treatment Market

Epithelioid Sarcoma Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Epithelioid Sarcoma Epidemiology Segmentation:

The Epithelioid Sarcoma market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:

• Total Prevalence of Epithelioid Sarcoma
• Prevalent Cases of Epithelioid Sarcoma by severity
• Gender-specific Prevalence of Epithelioid Sarcoma
• Diagnosed Cases of Episodic and Chronic Epithelioid Sarcoma

Download the report to understand which factors are driving Epithelioid Sarcoma epidemiology trends @ Epithelioid Sarcoma Epidemiology Forecast

Epithelioid Sarcoma Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Epithelioid Sarcoma market or expected to get launched during the study period. The analysis covers Epithelioid Sarcoma market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Epithelioid Sarcoma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Epithelioid Sarcoma Therapies and Key Companies

• Tazemetostat in Combination With Doxorubicin: Epizyme, Inc.
• Doxorubicin HCl: Ipsen
• Talimogene Laherparepvec (T-VEC): Amgen

Discover more about therapies set to grab major Epithelioid Sarcoma market share @ Epithelioid Sarcoma Treatment Market

Scope of the Epithelioid Sarcoma Market Report

• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Epithelioid Sarcoma Companies: Epizyme, Inc., Ipsen, Amgen, and others
• Key Epithelioid Sarcoma Therapies: Tazemetostat in Combination With Doxorubicin, Doxorubicin HCl, Talimogene Laherparepvec (T-VEC), and others
• Epithelioid Sarcoma Therapeutic Assessment: Epithelioid Sarcoma current marketed and Epithelioid Sarcoma emerging therapies
• Epithelioid Sarcoma Market Dynamics: Epithelioid Sarcoma market drivers and Epithelioid Sarcoma market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Epithelioid Sarcoma Unmet Needs, KOL’s views, Analyst’s views, Epithelioid Sarcoma Market Access and Reimbursement

To know more about Epithelioid Sarcoma companies working in the treatment market, visit @ Epithelioid Sarcoma Clinical Trials and Therapeutic Assessment

Table of Contents

1. Epithelioid Sarcoma Market Report Introduction

2. Executive Summary for Epithelioid Sarcoma

3. SWOT analysis of Epithelioid Sarcoma

4. Epithelioid Sarcoma Patient Share (%) Overview at a Glance

5. Epithelioid Sarcoma Market Overview at a Glance

6. Epithelioid Sarcoma Disease Background and Overview

7. Epithelioid Sarcoma Epidemiology and Patient Population

8. Country-Specific Patient Population of Epithelioid Sarcoma

9. Epithelioid Sarcoma Current Treatment and Medical Practices

10. Epithelioid Sarcoma Unmet Needs

11. Epithelioid Sarcoma Emerging Therapies

12. Epithelioid Sarcoma Market Outlook

13. Country-Wise Epithelioid Sarcoma Market Analysis (2019-2032)

14. Epithelioid Sarcoma Market Access and Reimbursement of Therapies

15. Epithelioid Sarcoma Market Drivers

16. Epithelioid Sarcoma Market Barriers

17. Epithelioid Sarcoma Appendix

18. Epithelioid Sarcoma Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/conference-coverage-services